Academic Journals Database
Disseminating quality controlled scientific knowledge

Chitosan IFN-γ-pDNA Nanoparticle (CIN) Therapy for Allergic Asthma

ADD TO MY LIST
 
Author(s): Kumar Mukesh | Kong Xiaoyuan | Behera Aruna | Hellermann Gary | Lockey Richard | Mohapatra Shyam

Journal: Genetic Vaccines and Therapy
ISSN 1479-0556

Volume: 1;
Issue: 1;
Start page: 3;
Date: 2003;
Original page

ABSTRACT
Abstract Background Allergic subjects produce relatively low amounts of IFN-γ, a pleiotropic Th-1 cytokine that downregulates Th2-associated airway inflammation and hyperresponsiveness (AHR), the hallmarks of allergic asthma. Adenovirus-mediated IFN-γ gene transfer reduces AHR, Th2 cytokine levels and lung inflammation in mice, but its use would be limited by the frequency of gene delivery required; therefore, we tested chitosan/IFN-γ pDNA nanoparticles (CIN) for in situ production of IFN-γ and its in vivo effects. Methods CIN were administered to OVA-sensitized mice to investigate the possibility of using gene transfer to modulate ovalbumin (OVA)-induced inflammation and AHR. Results Mice treated with CIN exhibit significantly lower AHR to methacholine challenge and less lung histopathology. Production of IFN-γ is increased after CIN treatment while the Th2-cytokines, IL-4 and IL-5, and OVA-specific serum IgE are reduced compared to control mice. AHR and eosinophilia are also significantly reduced by CIN therapy administered therapeutically in mice with established asthma. CIN was found to inhibit epithelial inflammation within 6 hours of delivery by inducing apoptosis of goblet cells. Experiments performed on STAT4-defective mice do not show reduction in AHR with CIN treatment, thus implicating STAT4 signaling in the mechanism of CIN action. Conclusion These results demonstrate that mucosal CIN therapy can effectively reduce established allergen-induced airway inflammation and AHR.
Why do you need a reservation system?      Save time & money - Smart Internet Solutions